Estrogen receptor modulators and uses thereof

A compound that has the following structure of Formula (IIa):

• stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein:
• Z1 and Z2 are independently —O—, —(CH2)—, —C(O)—, or a bond;
• Cy is C6-C20 aryl, C3-C12 carbocyclyl, C2-C20 heterocyclyl, or C1-C20 heteroaryl;
• X is —(CH2)—;
• R1 is H, F, Cl, —CN, —CH2OH, —CH(CH3)OH, —C(CH3)2OH, —CH(CF3)OH, —CH2F, —CHF2, —CH2CHF2, —CF3, —CH3, —C(O)NH2, —C(O)NHCH3, or —C(O)N(CH3)2;
• each R2 and each R3 are independently halogen, —CN, —OR10, —NR13R14, C1-C4 alkyl, —C1-C4 alkyl-OH, —OC2-C4 alkyl-OH, C1-C4 fluoroalkyl, —C(═O)OR12, —NHC(═O)R11, —C(═O)NHR12, —SO2R11, —NHSO2R11, or —SO2NHR12;
• R6 is H, halogen, C1-C6 alkyl, or C1-C6 fluoroalkyl;
• each R10 is independently H, C1-C4 alkyl, or C1-C4 fluoroalkyl;
• each R11 is independently C1-C4 alkyl or C1-C4 fluoroalkyl;
• each R12 is independently H, C1-C4 alkyl, or C1-C4 fluoroalkyl;
• each R13 and each R14 are independently H or C1-C4 alkyl;
• m is 0, 1, 2 or 3;
• and
• n is 0, 1, 2 or 3;
• where carbocyclyl, heterocyclyl, aryl, and heteroaryl are optionally substituted with one or more groups independently comprising F, Cl, Br, I, —CN, —CH3, —CH2CH3, —CH(CH3)2, —CH2CH(CH3)2, —CH2OH, —CH2OCH3, —CH2CH2OH, —C(CH3)2OH, —CH(OH)CH(CH3)2, —C(CH3)2CH2OH, —CH2CH2SO2CH3, —CH2OP(O)(OH)2, —CH2F, —CHF2, —CF3, —CH2CF3, —CH2CHF2, —CH(CH3)CN, —C(CH3)2CN, —CH2CN, —CO2H, —COCH3, —CO2CH3, —CO2C(CH3)3, —COCH(OH)CH3, —CONH2, —CONHCH3, —CON(CH3)2, —C(CH3)2CONH2, —NH2, —NHCH3, —N(CH3)2, —NHCOCH3, —N(CH3)COCH3, —NHS(O)2CH3, —N(CH3)C(CH3)2CONH2, —N(CH3)CH2CH2S(O)2CH3, —NO2, ═O, —OH, —OCH3, —OCH2CH3, —OCH2CH2OCH3, —OCH2CH2OH, —OCH2CH2N(CH3)2, —OCF3, —OCHF2, —OP(O)(OH)2, —S(O)2N(CH3)2, —SCH3, —S(O)2CH3, —S(O)3H, cyclopropyl, oxetanyl, azetidinyl, 1-methylazetidin-3-yl)oxy, N-methyl-N-oxetan-3-ylamino, azetidin-1-ylmethyl, pyrrolidin-1-yl, and morpholino.